Skip to main content
SpringerLink
Log in

The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma

  • Article
  • Published:
Pathology Oncology Research

Abstract

To assess the significance of epidermal growth factor receptor family members, the overexpression of c-erbB-1 and c-erbB-2 was retrospectively investigated in 146 southern Iranian gastric cancer patients. Indirect immunostaining was used to evaluate the expression of these two receptors in formalin-fixed paraffin-embedded tissue samples. c-ErbB-1 expression was observed in 47 (32.2%) and c-erbB-2 expression was observed in 24 (16.4%) of tumors. Significant positive correlations were observed between c-erbB-1 expression and tumor size, local invasion, lymph node involvement and tumor stage. There was also a negative correlation between c-erbB-2 expression and tumor stage. These results may suggest the contribution of c-erbB-1 molecule in progression of gastric carcinomas in southern Iranian patients. Moreover, the relatively high percentage of c-erbB-2 positive tumors may provide a useful target for the immunotherapy of these cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Farahmandbeigi M, Kadivar MR: The incidence rate of registered cancers in Fars province. Disease Control Unit, Shiraz University Press, Iran, 2000.

    Google Scholar 

  2. Koyama S, Maruyama T, Adachi S: Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a twocolor flow-cytometric analysis. J Cancer Res Clin Oncol 125: 47–54, 1999.

    Article  PubMed  CAS  Google Scholar 

  3. Prakash I, Mathur RP, Kar P, et al: Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indi J Pathol Microbiol 40:481–490, 1997.

    CAS  Google Scholar 

  4. Jang WI, Yang WI, Lee CI, et al: Immunohistochemical detection of p53 protein, c-erbB-2 protein, epidermal growth factor receptor protein and proliferating cell nuclear antigen in gastric carcinoma. J Korean Med Sci 8: 293–304, 1993.

    PubMed  CAS  Google Scholar 

  5. Oshima CT, Lanzoni VP, Iriya K, Forones NM: C-erbB-2 oncoprotein in gastric carcinoma: correlation with clinical stage and prognosis. Int J Biol Markers 16: 250–254, 2001.

    PubMed  CAS  Google Scholar 

  6. Wu MS, Shun CT, Sheu JC, et al: Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. J Gastroenterol Hepatol 13: 305–310, 1998.

    PubMed  CAS  Google Scholar 

  7. Lee HR, Kim JH, Uhm HD, et al: Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 53: 192–197, 1996.

    Article  PubMed  CAS  Google Scholar 

  8. Aoyagi K, Kohfuji K, Yano S, et al: Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma. Kurume Med J 48:197–200, 2001.

    PubMed  CAS  Google Scholar 

  9. Motojima K, Furui J, Kohara N, et al: erbB-2 expression in welldifferentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 115:349–354, 1994.

    PubMed  CAS  Google Scholar 

  10. Yoshida K, Yasui W, Ito H, Tahara E: Growth factors in progression of human esophageal and gastric carcinomas. Exp Pathol 40: 291–300, 1990.

    PubMed  CAS  Google Scholar 

  11. Lee EY, Cibull ML, Strodel WE, Haley JV: Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. Arch Pathol Lab Med 118: 235–239, 1994.

    PubMed  CAS  Google Scholar 

  12. Orita H, Maehara Y, Emi Y, et al: c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology 44: 294–298, 1997.

    PubMed  CAS  Google Scholar 

  13. Tokunaga A, Onda M, Okuda T, et al: Prevention of growth of a human gastric cancer xenograft in nude mice with anti-EGF receptor ntibody. In: Takahashi T, editor. Recent advances in management of digestive cancers. Tokyo: Springer-Verlag, 403–405, 1993.

    Google Scholar 

  14. Teramoto T, Onda M, Tokunaga A, Asano G: Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer 77s: 1639–1645, 1996.

    Google Scholar 

  15. Ross JS, McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554–568, 2001.

    Article  PubMed  CAS  Google Scholar 

  16. Modjtahedi H, Hickish T, Nicolson M, et al: Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 73: 228–235, 1996.

    PubMed  CAS  Google Scholar 

  17. Bianco C, Bianco R, Tortora G, et al: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6: 4343–4350, 2000.

    PubMed  CAS  Google Scholar 

  18. Ciardiello F, Bianco R, Damiano V, et al: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739–47, 2000.

    PubMed  CAS  Google Scholar 

  19. Ciardiello F, Bianco R, Damiano V, et al: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909–916, 1999.

    PubMed  CAS  Google Scholar 

  20. Falcey J, Pfister D, Cohen R, et al: A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplastin in patients with head and neck or lung carcinomas. Proc Am Soc Clin Oncol 16: 1364, 1997.

    Google Scholar 

  21. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648, 1999.

    PubMed  CAS  Google Scholar 

  22. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792, 2001.

    Article  PubMed  CAS  Google Scholar 

  23. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726, 2002.

    Article  PubMed  CAS  Google Scholar 

  24. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61s: 58–66, 2001.

    Article  Google Scholar 

  25. Azzoli CG, Krug LM, Miller VA, et al: Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 29s: 59–65, 2002.

    Article  Google Scholar 

  26. Zinner RG, Kim J, Herbst RS: Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37: 17–27, 2002.

    Article  PubMed  Google Scholar 

  27. Leyland-Jones B: Maximizing the response to Herceptin therapy through optimal use and patient selection. Anticancer Drugs 4s: 11–17, 2001.

    Google Scholar 

  28. Modjtahedi H, Eccles SA, Box G, et al: Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophys 22: 129–146, 1993.

    PubMed  CAS  Google Scholar 

  29. Styles JM, Harrison S, Gusterson BA, Dean CJ: Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene. Int J Cancer 45: 320–324, 1990.

    Article  PubMed  CAS  Google Scholar 

  30. Walker RA: The erbB/HER type 1 tyrosine kinase receptor family. J Pathol 185: 234–235, 1998.

    Article  PubMed  CAS  Google Scholar 

  31. Peles E, Yarden Y: Neu and its ligands: from an oncogene to neural factors. Bioessays 15: 815–824, 1993.

    Article  PubMed  CAS  Google Scholar 

  32. Takehana T, Kunitomo K, Kono K, et al: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzymelinked immuno-sorbent assay. Int J Cancer 98: 833–837, 2002.

    Article  PubMed  CAS  Google Scholar 

  33. Gharesi-Fard B, Vasei M, Talei A, et al: The expression and prognostic significance of c-erbB-2 molecules in patients with breast cancer in Iran. Irn J Med Sci 25: 31–35, 2000.

    Google Scholar 

  34. Khademi B, Shirazi FM, Vasei M, et al: The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184: 223–230, 2002.

    Article  PubMed  CAS  Google Scholar 

  35. Shimada E, Kato M, Saito Y: Immunohistochemical study of the c-erbB-2 protein in human gastric carcinoma. Nippon Geka Gakkai Zasshi 94: 33–40, 1993.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Shiraz University of Medical Sciences, Iran

    Sa Maleck-Hosseini

  2. Shiraz Institute for Cancer Research (ICR), Shiraz University of Medical Sciences, P.O. Box:71345-3119, Shiraz, Iran

    Mohammad Vasei & Maliheh Khodami

  3. Department of Pathology, Shiraz University of Medical Sciences, Iran

    Abbas Ghaderi, Behronz Gharesi-Fard & Mehrnoosh Doroudchi

  4. Department of Surgery, Shiraz University of Medical Sciences, Iran

    Helmout Modjtahedi

Authors
  1. Abbas Ghaderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Vasei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sa Maleck-Hosseini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Behronz Gharesi-Fard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maliheh Khodami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mehrnoosh Doroudchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helmout Modjtahedi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abbas Ghaderi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghaderi, A., Vasei, M., Maleck-Hosseini, S. et al. The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol. Oncol. Res. 8, 252–256 (2002). https://doi.org/10.1007/BF03036740

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03036740

Keywords

Search

Navigation